We demonstrated that antibody-mediated Gal3 blockade results in the predicted inhibition of tumor signaling pathways and tumor cell invasion, with evidence of anti-tumor activity observed in animal tumor models expressing MUC16 as a candidate glycoprotein partner. Here, MUC16 is linked to neoplasm.